KPKristine B. Patterson

Kristine B. Patterson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kristine B. Patterson has a total of 142 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • “I Should Know Better”: The Roles of Relationships, Spirituality, Disclosure, Stigma, and Shame for Older Women Living With HIV Seeking Support in the South

    by Catherine A. Grodensky, Carol E. Golin, Chaunetta Jones, Meheret Mamo, Alexis C. Dennis, Melinda G. Abernethy, Kristine B. Patterson

    The population of older people living with HIV in the United States is growing. Little is known about specific challenges older HIV-infected women face in coping with the disease and its attendant stressors. To understand these issues for older women, we conducted semi-structured in-depth interviews with 15 women (13 African American, 2 Caucasian) 50 years of age and older (range 50-79 years) in HIV care in the southeastern United States, and coded transcripts for salient themes. Many women felt isolated and inhibited from seeking social connection due to reluctance to disclose their HIV status, which they viewed as more shameful at their older ages. Those receiving social support did so mainly through relationships with family and friends, rather than romantic relationships. Spirituality provided great support for all participants, although fear of disclosure led several to restrict connections with a church community. Community-level stigma-reduction programs may help older HIV-infected women receive support.


  • Differential penetration of raltegravir throughout gastrointestinal tissue

    by Kristine B. Patterson, Heather A. Prince, Trenton Stevens, Nicholas J. Shaheen, Evan S. Dellon, Ryan D. Madanick, Steven Jennings, Myron S. Cohen, Angela D.M. Kashuba

    Objective: To investigate the concentration of the integrase strand inhibitor raltegravir (RAL) throughout gastrointestinal (GI) tissue, especially gut-associated lymphoid tissue (GALT), as an adjunct to current prevention and cure strategies. Design: Open-label pharmacokinetic (PK) study. Methods: HIV-negative men received RAL 400 mg twice daily for 7 days. Seven blood plasma specimens were collected over 12-h intervals; timed tissue specimens from terminal ileum, splenic flexure, and rectum were also obtained by colonoscopy following the first dose and on day 7 [multiple dose (MD)]. RAL concentrations were measured by validated LC–MS assay with 1 ng/ml lower limit of detection. Data were analyzed by noncompartmental methods (WinNonlin 6). Tissue exposures are reported as composite medians and tissue density of 1.04 g/ml is assumed for comparisons. Results: Fourteen men completed evaluations. Median (range) age was 24 (19–49) years and BMI 25 (19–31) kg/m2. After the first dose, area under the time-concentration curve (AUC)0-12h was highest in the terminal ileum (594 μg*h/ml). Exposures were 160, 68 and 39-fold greater than blood plasma at the terminal ileum, splenic flexure and rectum, respectively. After multiple doses, exposure was highest at the splenic flexure (2240 μg*h/ml); exposure at the terminal ileum and rectum were equivalent (both 788 μg*h/ml). Following multiple doses, exposures were 160 to 650-fold greater than blood plasma throughout the colon. Conclusion: RAL rapidly disseminates into GI tissue and concentrations remain significantly higher than blood plasma. RAL exposure in GI tissue remains higher than any antiretroviral investigated to date. These data suggest that RAL should result in full suppression of viral replication in GI tissue and GALT.


  • Protein Binding of Lopinavir and Ritonavir During 4 Phases of Pregnancy

    by Kristine B. Patterson, Julie B. Dumond, Heather A. Pa-C Prince, Amanda J. Jenkins, Kimberly K. Scarsi, Ruili Wang, Stephanie Malone, Michael G. Hudgens, Angela D. M. Kashuba

    Objective: To investigate the intraindividual pharmacokinetics (PKs) of total (protein bound plus unbound) and unbound lopinavir/ritonavir (LPV/RTV) and to assess whether the pediatric formulation (100 mg/25 mg) can overcome any pregnancy-associated changes. Design: Prospective longitudinal PK study. Methods: HIV-infected pregnant antiretroviral therapy–naive and experienced women receiving LPV/RTV 400 mg/100 mg tablets twice daily. Intensive PK evaluations were performed at 20–24 weeks (PK1), 30 weeks (PK2) followed by empiric dose increase using the pediatric formulation (100 mg/25 mg twice daily), 32 weeks (PK3), and 8 weeks postpartum (PK4). Results: Twelve women completed prespecified PK evaluations. Median (range) age was 28 (18–35) years and baseline BMI was 32 (19–41) kg/m2. During pregnancy, total area under the time concentration (AUC0–12h) for LPV was significantly lower than postpartum (PK1, PK2, or PK3 vs. PK4, P = 0.005). Protein-unbound LPV AUC0–12h remained unchanged during pregnancy [PK1: 1.6 (1.3–1.9) vs. PK2: 1.6 (1.3–1.9) μg·h/mL, P = 0.4] despite a 25% dose increase [PK2 vs. PK3: 1.8 (1.3–2.1) μg·h/mL, P = 0.5]. Protein-unbound LPV predose concentrations (C12h) did not significantly change despite dose increase [PK2: 0.10 (0.08–0.15) vs. PK3: 0.12 (0.10–0.15) μg/mL, P = 0.09]. Albumin and LPV AUC0–12h fraction unbound were correlated (rs = 0.3, P = 0.03). Conclusions: Total LPV exposure was significantly decreased throughout pregnancy despite the increased dose. However, the exposure of unbound LPV did not change significantly regardless of trimester or dose. Predose concentrations of unbound LPV were not affected by the additional dose and were 70-fold greater than the minimum efficacy concentration. These findings suggest dose adjustments may not be necessary in all HIV-infected pregnant women.


  • Open Access

    Darunavir, Ritonavir, and Etravirine Pharmacokinetics in the Cervicovaginal Fluid and Blood Plasma of HIV-Infected Women

    by Kristine Patterson, Steven Jennings, Ron Falcon, Joseph Mrus, Angela Kashuba

    We report darunavir, ritonavir, and etravirine pharmacokinetics in cervicovaginal fluid and blood plasma for women from the G ender, R ace a nd C linical E xperience (GRACE) study. Eight women received darunavir-ritonavir (600/100 mg) twice daily (b.i.d.); two also received etravirine (200 mg) b.i.d. Week 4 paired blood plasma and cervicovaginal fluid samples were collected over 12 h. Darunavir and etravirine cervicovaginal fluid exposures were higher than blood plasma exposures; ritonavir cervicovaginal fluid exposure was lower than blood plasma exposure. The high exposures of darunavir and etravirine in cervicovaginal fluid warrant further evaluation of these drugs for use in HIV-1 prevention.


  • HIV and the Heart

    by Kristine B. Patterson, Joseph J. Eron

  • Contributors

    by Marschall S. Runge, George A. Stouffer, Cam Patterson, Charles Baggett, Frédérique Bailliard, Thomas M. Bashore, Sharon Ben-Or, Christoph Bode, Mark E. Boulware, Michael E. Bowdish, et al.

  • Open Access

    Treatment Responses in Antiretroviral Treatment–Naive Premenopausal and Postmenopausal HIV‐1–Infected Women: An Analysis from AIDS Clinical Trials Group Studies

    by Kristine B. Patterson, Susan E. Cohn, Jennifer Uyanik, Michael Hughes, Marlene Smurzynski, Joseph J. Eron

    Menopause may affect antiretroviral treatment (ART) response. Immunologic and virologic responses to ART were compared in 220 premenopausal and 47 po


  • Genital Tract, Cord Blood, and Amniotic Fluid Exposures of Seven Antiretroviral Drugs during and after Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women

    by Rosa F. Yeh, Naser L. Rezk, Angela D. M. Kashuba, Julie B. Dumond, Hiba L. Tappouni, Hsiao-Chuan Tien, Ya-Chi Chen, Manoli Vourvahis, Amanda L. Horton, Susan A. Fiscus, et al.

    The objective of the study was to measure antiretroviral exposures in four physiological compartments during pregnancy, delivery, and postpartum. This prospective, open-label, longitudinal study collected paired blood plasma (BP) and genital tract (GT) aspirates antepartum, at delivery, and up to 12 weeks postpartum. Antiretroviral cord BP and amniotic fluid concentrations were also measured. Drug concentrations were analyzed by validated high-performance liquid chromatography/UV and liquid chromatography/tandem mass spectrometry methods, with secondary compartment concentrations presented as the percentage of BP. Fourteen women taking lamivudine plus zidovudine and either lopinavir-ritonavir ( n = 7), nelfinavir ( n = 6), or nevirapine ( n = 1) were enrolled; four also received tenofovir. GT penetration relative to BP was highest for the nucleoside reverse transcriptase inhibitors compared to the protease inhibitors and nevirapine. Only antepartum nelfinavir GT penetration was significantly higher than in the second trimester (geometric mean ratio [GMR], 179.3) or third trimester (GMR, 41.9). Compared to nonpregnant historical controls, antepartum GT penetration was significantly lower ( P < 0.05) for zidovudine (GMR, 0.25) and lopinavir (GMR, 0.03); postpartum lopinavir GT penetration continued to be significantly lower (GMR, 0.27). Cord BP exposures were highest for lamivudine and tenofovir (≥100%), with cord BP levels of the remaining drugs ranging from 49 to 86% of that of the respective BP level. Amniotic exposures for lamivudine, zidovudine, tenofovir, and nelfinavir were ≥100%, nevirapine exposure was 53%, and lopinavir and ritonavir exposures were ≤6% that of BP. We conclude that GT, cord BP, and amniotic fluid exposures vary within and between antiretroviral drug classes and biologic sites. Measurement of antiretroviral exposure in maternal genital secretions, cord BP, and amniotic fluid may be needed to identify signals of subtherapeutic or supratherapeutic drug exposure.


  • Frequent detection of acute HIV infection in pregnant women

    by Kristine B Patterson, Peter A Leone, Susan A Fiscus, JoAnn Kuruc, Sandra I McCoy, Leslie Wolf, Evelyn Foust, Del Williams, Joseph J Eron, Christopher D Pilcher

    Background: Universal prenatal HIV antibody testing, which does not detect acute HIV, is standard for pregnant women in the United States. Unrecognized HIV acquisition during pregnancy may result in higher rates of perinatal transmission. Objective: To determine the prevalence of acute (antibody-negative) HIV infection in pregnant women and to assess the potential for prompt initiation of antiretroviral therapy to prevent perinatal transmission. Methods: From 1 November 2002 to 30 April 2005, all publicly funded HIV testing sites participated in North Carolina's Screening and Tracing Active Transmission (STAT) Program, which retested all specimens that were HIV antibody negative for HIV RNA using specimen pooling. All patients with acute HIV infection were immediately traced for evaluation, confirmatory testing, counseling, and referral services. For this study, all pregnant women with acute HIV were immediately initiated onto antiretroviral therapy and followed prospectively for pregnancy outcomes. Results: During the study period, 443 women were HIV positive by antibody testing; 15 were HIV antibody negative but positive by RNA assay and of these five were pregnant at the time of testing. The pregnant women received antiretroviral drugs and delivered HIV-uninfected infants. Maternal testing records of all six HIV-infected infants born in North Carolina showed three mothers with chronic HIV infection and three HIV antibody negative at private prenatal testing facilities. Conclusions: In resource-rich settings, a substantial proportion of residual perinatal transmission may be from HIV acquisition during pregnancy. Standard antibody tests miss acute HIV infection and so algorithms that include pooled HIV RNA testing may improve its detection and represent a further opportunity to prevent perinatal transmission.


  • Open Access

    Effects of age and sex on immunological and virological responses to initial highly active antiretroviral therapy

    by K Patterson, S Napravnik, J Eron, J Keruly, R Moore

    Background Highly active antiretroviral therapy (HAART) has increased longevity. Currently, women comprise >50% of HIV‐infected individuals worldwide. It is not known if there are differences between the sexes in the immunological and virological responses to HAART across the age strata. Methods Immunological reconstitution and virological response in the first 6 months of a first HAART regimen in two observational clinical HIV‐infected cohorts were compared by both sex and age (≥50 vs. P=0.81) and no differences in virological suppression, even after adjusting for type of HAART (P=0.68) or restricting the analysis to women only (P=0.81). These results suggest that younger and older women and men may have similar short‐term initial HAART outcomes. Conclusions Further evaluation of longer term clinical response to initial HAART regimen based on sex and age is indicated, especially with more efficacious and simplified antiretroviral regimens and the associated decrease in mortality.